Genocea Biosciences (NASDAQ: GNCA) announced that top-line results from a Phase 2a clinical trial for GEN-004, its universal vaccine candidate ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE